Once again, Novo's semaglu­tide shows car­dio­vas­cu­lar ben­e­fit, weight loss — this time in adults with heart fail­ure

No­vo Nordisk’s GLP-1 We­govy has shown car­dio­vas­cu­lar ben­e­fit again, this time in the Phase III STEP HF­pEF tri­al, on top of the ex­pect­ed weight loss, the com­pa­ny an­nounced at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy (ESC) Con­gress to­day.

Against place­bo, 2.4 mg of We­govy (semaglu­tide) showed “large” re­duc­tions in heart fail­ure-re­lat­ed symp­toms and phys­i­cal lim­i­ta­tions, as well as im­prove­ments in ex­er­cise func­tion and weight loss in adults with heart fail­ure with pre­served ejec­tion frac­tion (HF­pEF) and obe­si­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.